Elanco Animal Health (NYSE:ELAN) Coverage Initiated by Analysts at The Goldman Sachs Group

Stock analysts at The Goldman Sachs Group began coverage on shares of Elanco Animal Health (NYSE:ELAN) in a research report issued on Friday, Benzinga reports. The brokerage set a “buy” rating and a $32.00 price target on the stock. The Goldman Sachs Group’s price target points to a potential upside of 36.09% from the company’s current price.

A number of other equities analysts also recently issued reports on the stock. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. UBS Group boosted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. TD Cowen upped their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.91.

Elanco Animal Health Stock Up 4.3%

ELAN stock opened at $23.51 on Friday. Elanco Animal Health has a fifty-two week low of $19.40 and a fifty-two week high of $27.98. The business’s 50-day moving average is $23.19 and its two-hundred day moving average is $23.58. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The company has a market cap of $11.75 billion, a price-to-earnings ratio of -57.35, a P/E/G ratio of 1.61 and a beta of 1.70.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Shiv O’Neill purchased 3,998 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the transaction, the insider directly owned 87,832 shares in the company, valued at $2,071,078.56. This trade represents a 4.77% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Lawrence Kurzius acquired 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 63,198 shares of company stock valued at $1,473,109. Insiders own 1.14% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Mitchell & Pahl Private Wealth LLC boosted its holdings in Elanco Animal Health by 5.1% in the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 53,938 shares of the company’s stock worth $1,208,000 after buying an additional 2,624 shares during the period. NorthCrest Asset Manangement LLC bought a new stake in Elanco Animal Health during the third quarter valued at about $290,000. Wedmont Private Capital raised its holdings in Elanco Animal Health by 38.0% during the third quarter. Wedmont Private Capital now owns 12,948 shares of the company’s stock valued at $292,000 after acquiring an additional 3,564 shares during the period. GAMMA Investing LLC lifted its position in shares of Elanco Animal Health by 14.1% in the third quarter. GAMMA Investing LLC now owns 14,199 shares of the company’s stock valued at $318,000 after acquiring an additional 1,750 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Elanco Animal Health by 12.5% in the third quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company’s stock valued at $94,000 after acquiring an additional 464 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.